CP
ALNY icon

Covenant Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Covenant Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-604
Closed -$240K – 8
2025
Q4 		$240K Hold
604
– – 0.07% 113
2025
Q3 		$275K Buy
+604
New +$246K 0.08% 108

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Covenant Partners's ALNY Position: Q1 2026 in Review

Covenant Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 604 shares — an estimated $240K sold.

Covenant Partners first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $275K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Covenant Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Covenant Partners sold 604 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $240K.
  • Covenant Partners first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Covenant Partners's Alnylam Pharmaceuticals position peaked at $275K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.